Pathology & Genomics

病理

基本信息

批准号：
10673949
负责人：
David A Barbie
金额：
$ 30.6万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-01 至 2027-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10673949
关键词：
Alleles Anatomy Antibodies Area Biochemical Pathway Biochemical Process Biological Biological Assay Biological Markers Cancer Biology Cancer Center Caring Cells Certification Clinical Clinical Pathology Clinical Treatment Complement Custom Dana-Farber Cancer Institute Databases Detection of Minimal Residual Disease Development Diagnosis Disease Epidermal Growth Factor Receptor Erlotinib Etiology Expression Profiling Gefitinib Gene Expression Profiling Genetic Genomics Genotype Goals Histologic Hybrids Image Immune Immunofluorescence Immunologic Immunohistochemistry Immunophenotyping In Situ Individual International Intervention Ions Knowledge Laboratories Malignant Neoplasms Malignant neoplasm of lung Manuals Massive Parallel Sequencing Measures Medicine Microscopic Molecular Molecular Genetics Monitor Multiplexed Ion Beam Imaging Mutation Oncogenic Pathologist Pathology Patient Monitoring Patient Selection Patients Periodicity Plasma Procedures Proteins Protocols documentation Quality Control RNA analysis ROS1 gene Reproduction spores Research Research Personnel Resources Sampling Scanning Selection for Treatments Seminal Services Slide Specimen Structure of parenchyma of lung Supervision System Techniques Technology Tissue Banks Tissue Microarray Tissue Sample Tissues Transcript Translational Research Tumor Tissue Validation Vertebral column Work automated image analysis automated segmentation cancer cell crizotinib design detection assay immune cell infiltrate immunoregulation improved inhibitor innovation molecular pathology nano-string next generation sequencing novel novel marker protein biomarkers protein expression quality assurance response sample collection sequencing platform skills standard of care transcriptomics treatment and outcome tumor tumor DNA tumor microenvironment

项目摘要

Project Summary: The Integrated Pathology and Genomics Core provides state-of-the-art analytic services for lung cancer samples spanning the full spectrum from initial sample handling and processing, to microscopic analysis by certified anatomic pathologists, to immunophenotypic analysis, to molecular genetic and genomic analysis. This work constitutes the backbone of lung cancer management, and enables the diagnosis and proper treatment selection for patients with lung cancers of all types, and also enables research into cancer biology, etiology, and management. Our pathology core has supported work that has led to major advances in the understanding of lung cancer biology, and associated management thereof, including seminal discoveries of the importance of mutations in EGFR, ALK, ROS1, and MET in lung cancer, the diagnosis and management of which have become the international standard-of-care in this area of medicine. In the same manner, we intend to continue our work to advance the understanding and care of lung cancer, by supporting the new projects proposed herein, with a combination of standard-of-care and innovative new cutting-edge technologies. In this SPORE proposal, we will support each of the proposed projects with a combination of standard-of-care clinical pathology services - such as histologic characterization of tumors, immunohistochemical assessment of protein expression, and massively parallel sequencing of tumor DNA - and innovative new techniques. Among the innovative new techniques to be deployed for this project are customized allele-specific PCR assays for individual fusion transcripts to enable ultrasensitive monitoring of cell-free circulating ALK rearrangements in plasma samples, cyclic immunofluorescence and transcriptomics for simultaneous in situ spatial expression of multiple proteins and transcripts involved in various biochemical pathways, and multiplexed ion beam imaging to provide high-order assessment of immune cell infiltrates within and adjacent to cancers.

项目概要：综合病理学和基因组学核心为肺癌样本提供最先进的分析服务涵盖从最初的样品处理和加工到经认证的微观分析的全范围解剖病理学家、免疫表型分析、分子遗传学和基因组分析。这部作品构成肺癌管理的支柱，使诊断和正确的治疗选择成为可能适用于所有类型的肺癌患者，还可以研究癌症生物学、病因学和管理。我们的病理学核心支持的工作在理解方面取得了重大进展肺癌生物学及其相关管理，包括重要发现的开创性发现肺癌中 EGFR、ALK、ROS1 和 MET 突变，其诊断和治疗已成为该医学领域的国际护理标准。以同样的方式，我们打算继续我们的工作通过支持本文提出的新项目，促进对肺癌的理解和护理标准护理和创新的尖端技术的结合。在此 SPORE 提案中，我们将结合护理标准来支持每个拟议项目临床病理学服务 - 例如肿瘤的组织学特征、免疫组织化学评估蛋白质表达、肿瘤 DNA 大规模并行测序以及创新新技术。之中该项目将采用的创新新技术是定制的等位基因特异性 PCR 检测单个融合转录本能够超灵敏地监测无细胞循环 ALK 重排血浆样本、循环免疫荧光和转录组学，用于同步原位空间表达参与各种生化途径的多种蛋白质和转录本，以及多重离子束成像提供对癌症内部和邻近免疫细胞浸润的高级评估。